Allianz Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Allianz Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-19,189	Closed	-$2.22M	–	2277
2023 Q3	$2.22M	Sell	19,189 -17,471	-48%	-$1.88M	﹤0.01%	1390
2023 Q2	$3.77M	Buy	36,660 +1,273	+4%	+$134K	0.01%	980
2023 Q1	$3.86M	Sell	35,387 -181,347	-84%	-$20M	0.01%	1072
2022 Q4	$24.7M	Sell	216,734 -48,188	-18%	-$4M	0.05%	409
2022 Q3	$16.4M	Sell	264,922 -2,004,173	-88%	-$140M	0.03%	522
2022 Q2	$181M	Sell	2,269,095 -470,270	-17%	-$44.5M	0.17%	130
2022 Q1	$288M	Sell	2,739,365 -88,355	-3%	-$8.61M	0.21%	106
2021 Q4	$305M	Sell	2,827,720 -178,732	-6%	-$19.5M	0.21%	103
2021 Q3	$329M	Buy	3,006,452 +70,560	+2%	+$7.33M	0.26%	85
2021 Q2	$275M	Buy	2,935,892 +38,354	+1%	+$3.53M	0.23%	95
2021 Q1	$267M	Sell	2,897,538 -306,378	-10%	-$25.9M	0.26%	90
2020 Q4	$234M	Sell	3,203,916 -472,882	-13%	-$35.1M	0.23%	97
2020 Q3	$286M	Buy	3,676,798 +1,249,989	+52%	+$86M	0.33%	63
2020 Q2	$135M	Buy	2,426,809 +363,266	+18%	+$15.5M	0.16%	143
2020 Q1	$61.1M	Buy	2,063,543 +908,002	+79%	+$30.7M	0.08%	268
2019 Q4	$41.8M	Sell	1,155,541 -120,073	-9%	-$3.68M	0.04%	489
2019 Q3	$34.8M	Buy	1,275,614 +192,749	+18%	+$4.98M	0.03%	557
2019 Q2	$26.1M	Buy	1,082,865 +273,497	+34%	+$6.94M	0.02%	695
2019 Q1	$21.4M	Buy	809,368 +741,532	+1,093%	+$17.6M	0.02%	728
2018 Q4	$1.32M	Sell	67,836 -42,557	-39%	-$834K	﹤0.01%	1919
2018 Q3	$2.16M	Sell	110,393 -35,977	-25%	-$684K	﹤0.01%	1908
2018 Q2	$2.42M	Buy	+146,370	New	+$2.23M	﹤0.01%	1860
2016 Q4	–	Sell	-87,499	Closed	-$1.58M	–	2720
2016 Q3	$1.58M	Sell	87,499 -1,093,870	-93%	-$21.4M	﹤0.01%	2075
2016 Q2	$19.5M	Sell	1,181,369 -5,459	-0.5%	-$88.3K	0.02%	919
2016 Q1	$19.7M	Sell	1,186,828 -15,597	-1%	-$273K	0.02%	794
2015 Q4	$26.5M	Buy	1,202,425 +547,257	+84%	+$10.7M	0.03%	619
2015 Q3	$13M	Buy	655,168 +224,633	+52%	+$7.1M	0.02%	874
2015 Q2	$15M	Sell	430,535 -77,226	-15%	-$2.36M	0.02%	924
2015 Q1	$13.2M	Sell	507,761 -379,250	-43%	-$6.95M	0.02%	849
2014 Q4	$11.4M	Buy	887,011 +19,871	+2%	+$249K	0.01%	907
2014 Q3	$10.6M	Sell	867,140 -287,832	-25%	-$3.34M	0.01%	814
2014 Q2	$18.3M	Buy	1,154,972 +223,502	+24%	+$3.19M	0.02%	588
2014 Q1	$14.1M	Buy	931,470 +62,227	+7%	+$703K	0.02%	652
2013 Q4	$6.62M	Buy	+869,243	New	+$4.69M	0.01%	865

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Allianz Asset Management's HZNP Position: Q4 2023 in Review

Allianz Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 19,189 shares — an estimated $2.22M sold.

Allianz Asset Management first reported a position in HZNP in Q4 2013 and held it in 34 quarters. The position peaked at $329M in Q3 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Allianz Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Allianz Asset Management sold 19,189 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $2.22M.
Allianz Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 34 quarters.
Allianz Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $329M in Q3 2021.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Allianz Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.